Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Endava, Lowers Price Target to $112

Needham analyst Mayank Tandon maintains Endava (NYSE:DAVA) with a Buy and lowers the price target from $135 to $112.

byBenzinga Newsdesk

September 27, 2022

1 minute read

Needham analyst Mayank Tandon maintains Endava (NYSE:DAVA) with a Buy and lowers the price target from $135 to $112.

USA Markit Manufacturing PMI for Aug 61.200 vs 62.500 Est; Prior 63.400

By Benzinga Newsdesk

Today, 7:34 AM

USA Markit Manufacturing PMI for Aug 61.200 vs 62.500 consensus estimate. The prior reading was 63.400.

SPY

Information Services Q1 EPS $0.12 Beats $0.07 Estimate, Sales $73.00M Beat $69.96M Estimate

By Michael Horton

Today, 7:34 AM

Information Services (NASDAQ:III) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.07 by 71.43 percent. This is a 20 percent increase over earnings of $0.10 per share from

III

Jasper Therapeutics Q4 EPS $(0.36), Inline

By Happy Mohamed

Today, 7:34 AM

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 44 percent decrease over losses of $(0.25) per share from the same period last year.

JSPR

Stephens & Co. Downgrades Midland States Bancorp to Equal-Weight, Lowers Price Target to $28

By Benzinga Newsdesk

Today, 7:34 AM

Stephens & Co. analyst Terry McEvoy downgrades Midland States Bancorp (NASDAQ:MSBI) from Overweight to Equal-Weight and lowers the price target from $30 to $28.

MSBI

Needham Maintains Buy on Endava, Lowers Price Target to $112

Related Posts

USA Markit Manufacturing PMI for Aug 61.200 vs 62.500 Est; Prior 63.400

Information Services Q1 EPS $0.12 Beats $0.07 Estimate, Sales $73.00M Beat $69.96M Estimate

Jasper Therapeutics Q4 EPS $(0.36), Inline

Stephens & Co. Downgrades Midland States Bancorp to Equal-Weight, Lowers Price Target to $28